SCHEMBL7082013

SCHEMBL7082013

Cc1no[n+]([O-])c1[N+](=O)[O-]

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCC1 P33527 3/20 0.50
ABCB1 P08183 2/20 0.50
CA12 O43570 3/20 0.44
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44
CA9 Q16790 3/20 0.44
MAPT P10636 3/20 0.36
MAPK1 P28482 3/20 0.36
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
PKM P14618 2/20 0.36
ALDH1A1 P00352 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
NPC1 O15118 2/20 0.33
HTT P42858 2/20 0.33
RAB9A P51151 2/20 0.33
USP2 O75604 1/20 0.33
S100A4 P26447 1/20 0.33
ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9014154 0.77 ABCC1 (0.51) ABCC1ABCB1CA12CA1CA2
SCHEMBL8649331 0.75 ABCC1 (0.50) ABCC1ABCB1CA12CA1CA2
SCHEMBL30262276 0.73 ABCC1 (0.49) ABCC1ABCB1CA12CA1CA2
SCHEMBL31439271 0.71 ABCC1 (0.50) ABCC1ABCB1CA12CA1CA2
SCHEMBL31439265 0.71 ABCC1 (0.50) ABCC1ABCB1CA12CA1CA2
SCHEMBL29765264 0.71 ABCC1 (0.58) ABCC1ABCB1CA12CA1CA2
SCHEMBL28898103 0.67 ABCC1 (0.46) ABCC1ABCB1CA12CA1CA2
SCHEMBL30892508 0.64 ABCC1 (0.40) ABCC1ABCB1CA12CA1CA2
SCHEMBL8259009 0.62 CA12 (0.48) ABCC1ABCB1CA12CA1CA2
SCHEMBL31188779 0.62 ABCC1 (0.50) ABCC1ABCB1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6617339-B1 5-Isoxazolyloxymethyl-3-((dihydroxypropanoyl)-4-tetrahydropyri dyl-3,5- difluorophenyl)oxazolidinone, or the phosphated derivative or its disodium salt; antibiotic with useful activity against Grampositive pathogens SYNGENTA LIMITED (GB) 2003-09-09 US disclosed
US-20030144263-A1 Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them SYNGENTA LIMITED (GB) 2003-07-31 US disclosed
EP-1082323-A2 OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AstraZeneca UK Limited (GB) 2001-03-14 EP disclosed
WO-1999064417-A2 OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ASTRAZENECA AB (SE) 1999-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144263-A1 Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them CYP3A5, CYP2D6, OXA1L ABCC1 1206/4885ABCB1 394/4885CA12 3379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.